Impact of Neutrophil Extracellular Traps on Tissue Plasminogen Activator Induced Thrombolysis in Acute Ischemic Stroke Patients

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02907736

Acronym

THROMBONETS

Enrollment

Registered

2016-09-20

Start date

2015-11-12

Completion date

2017-07-01

Last updated

2018-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Stroke

Brief summary

Acute Ischemic stroke (AIS) remains a leading cause of adult disability, cognitive impairment and mortality worldwide despite the development of revascularization therapies (intravenous Tissue Plasminogen Activator (t-PA) and endovascular therapy). Thrombosis resistance after IV t-PA therapy is frequent especially in case of AIS with proximal occlusion. In recent years, neutrophil extracellular traps (NETs) have been identified as major triggers and structural factors of various forms of thrombosis. NETs are extracellular webs primarily composed of DNA from neutrophils. A recent study shows that the NETs burden in coronary thrombi is positively correlated with the infarct size and negatively correlated with electrocardiogram (ST-segment) resolution. This later study revealed that in vitro addition of DNase I accelerated the t-PA-induced thrombolysis of coronary thrombi. NETs could, in consequence, be promising targets for improved thrombolysis in AIS. The aim of this study is to assess the impact of NETs composition of thrombi retrieved during endovascular therapy in AIS patients on IV t-PA induced thrombolysis, clinical outcome and AIS etiologies.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* age \> 18 years old * AIS secondary to a large vessel occlusion * admitted for endovascular therapy.

Exclusion criteria

* Pregnant or breast feeding patient patient under legal protection * Patient opposition to participate in this study

Design outcomes

Primary

Measure	Time frame	Description
white cells counts	baseline	quantitative assessment of the relative fractions of the main constituents after Hematoxylin and Eosin staining
platlet counts	baseline	quantitative assessment of the relative fractions of the main constituents after Hematoxylin and Eosin staining
thrombus origin	baseline	according to the etiology of the stroke (TOAST classification)
red cells counts	baseline	quantitative assessment of the relative fractions of the main constituents after Hematoxylin and Eosin staining :

Countries

France

Outcome results